Adrian Varela, MD
Otolaryngology · Milwaukie, ORNPI 1366452054
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,261 of the $4,562 with a category attached, or 71.5%. 18 manufacturers reported payments, led by Intersect ENT, Inc. at 54.3% of the total. Reporting peaked in 2019 at $2,277 and has fallen 72.1% since, to $635 in 2025.
Across 101 payments — averaging $45.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intersect ENT, Inc.$2K
- GSK$449
- Regeneron Healthcare Solutions, Inc.$336
- Medtronic$324
- Sanofi$205
- Alk-abello, Inc$196
- plus $576 from 12 others
What the payments were for
- Travel & lodging$1,30129%
- Food & beverage$3,26171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intersect ENT, Inc. | 26 | $2,476 |
| GSK | 23 | $449 |
| Regeneron Healthcare Solutions, Inc. | 9 | $336 |
| Medtronic(2 entities) | 4 | $324 |
| Sanofi | 8 | $205 |
| Alk-abello, Inc | 9 | $196 |
| AstraZeneca | 5 | $181 |
| KARL Storz Endoscopy-america | 3 | $144 |
| Optinose US, Inc. | 3 | $64 |
| Aerin Medical Inc. | 2 | $44 |
| Acclarent, Inc | 2 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Novartis | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $17 |
| Circassia Inc. | 1 | $16 |
| Jubilant Hollisterstier LLC | 1 | $13 |
| Stryker | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,562 in reported general payments places this provider in the 85th percentile of 128 otolaryngology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 13 | $68,697 |
| Ipratropium Bromide | 45 | $891 |
| Azelastine Hcl | 45 | $872 |
| Omeprazole | 59 | $853 |
| Ofloxacin | 30 | $817 |
| Fluticasone Propionate | 12 | $448 |
| Mometasone Furoate | 33 | $425 |
| Tramadol Hcl | 17 | $211 |
| Mupirocin | 21 | $156 |
| Prednisone | 31 | $128 |
| Montelukast Sodium | 12 | $5 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Milwaukie
- Andrew BakerMilwaukie$8K
- Mathew GeltzeilerPortland$221K
- Ryan LiPortland$160K
- Jeremiah AltPortland$89K
- Mark WaxPortland$20K
- Marcus MonroePortland$16K
- Joshua SchindlerPortland$8K
- Daniel ClayburghPortland$7K
- Timothy HullarPortland$7K
- Paul FlintPortland$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.